Cost-effectiveness of hepatitis B vaccination using HEPLISAV in selected adult populations compared to Engerix-B vaccine
Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23707166

DOI
10.1016/j.vaccine.2013.05.014

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Aged; Cost-Benefit Analysis; Diabetes Mellitus /economics /virology; Health Personnel; Hepatitis B /prevention & control; Hepatitis B Vaccines /administration & dosage /economics /therapeutic use; Humans; Kidney Failure, Chronic /economics /virology; Markov Chains; Middle Aged; Models, Economic; Models, Theoretical; Probability; Renal Insufficiency, Chronic /economics /virology; Young Adult

AccessionNumber
22013022412

Date bibliographic record published
21/06/2013